Personalized and regenerative medicines are promising but they are complex to develop and require highly-flexible advanced manufacturing techniques that are still too manually intensive and costly.
Kurt Elam joined ACC/Lab Owl in 2017 with 20+ years of specialty biopharmaceutical experience, focused primarily on oncology, infectious disease, and critical care/ICU medicine. He has overseen and managed the successful launch of over 16 new FDA approved products/compounds or new indications, and worked to gain formulary approval in managed care organizations, thereby improving access for patients.
While there is tremendous excitement and ample investment around cell and gene therapy and regenerative medicine, several challenges, including scale-up, high manufacturing costs, and regulatory hurdles, continue to be impediments to the industry achieving its potential.
This webinar will host several industry leaders to discuss the latest in Lab automation solutions for small scale biotech laboratories all the way to commercial manufacturing operations.
